Guardant Health to end four-day selloff on Medicare Coverage for tissue-based cancer test

designer491/iStock via Getty Images

• Guardant Health (GH +5.1%) is set to close higher for the first time in four sessions on Tuesday after the precision oncology company announced a favorable decision on Medicare coverage for its Guardant360 TissueNext test.
• Widening the public access to the test, Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has issued coverage for Guardant360 TissueNext under the existing local coverage determination (LCD), the company said.
• Accordingly, Guardant360 TissueNext will be available for Medicare fee-for-service patients as a standalone service.
• TissueNext is a tissue-based test to identify patients with advanced cancer who can benefit from biomarker-driven therapy.
• Last June, Guardant Health (NASDAQ:GH) unveiled the test with its Guardant360 Response test, a liquid biopsy test designed to detect the circulating genetic material of cancer.

Comments

[LRNMO25]

This is a winner at todays sp.